These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15455144)

  • 1. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.
    Andrews MJ; McInnes C; Kontopidis G; Innes L; Cowan A; Plater A; Fischer PM
    Org Biomol Chem; 2004 Oct; 2(19):2735-41. PubMed ID: 15455144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
    Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
    ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein conformational transitions coupled to binding in molecular recognition of unstructured proteins: deciphering the effect of intermolecular interactions on computational structure prediction of the p27Kip1 protein bound to the cyclin A-cyclin-dependent kinase 2 complex.
    Verkhivker GM
    Proteins; 2005 Feb; 58(3):706-16. PubMed ID: 15609350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disordered p27Kip1 exhibits intrinsic structure resembling the Cdk2/cyclin A-bound conformation.
    Sivakolundu SG; Bashford D; Kriwacki RW
    J Mol Biol; 2005 Nov; 353(5):1118-28. PubMed ID: 16214166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
    Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
    J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex.
    De Vivo M; Cavalli A; Bottegoni G; Carloni P; Recanatini M
    Proteins; 2006 Jan; 62(1):89-98. PubMed ID: 16292742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.
    Andrews MJ; Kontopidis G; McInnes C; Plater A; Innes L; Cowan A; Jewsbury P; Fischer PM
    Chembiochem; 2006 Dec; 7(12):1909-15. PubMed ID: 17051658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads.
    Castanedo G; Clark K; Wang S; Tsui V; Wong M; Nicholas J; Wickramasinghe D; Marsters JC; Sutherlin D
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1716-20. PubMed ID: 16384702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural prediction of the interaction of the tumor suppressor p27
    Li J; Vervoorts J; Carloni P; Rossetti G; Lüscher B
    BMC Bioinformatics; 2017 Jan; 18(1):15. PubMed ID: 28056778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CK2 regulates in vitro the activity of the yeast cyclin-dependent kinase inhibitor Sic1.
    Barberis M; Pagano MA; Gioia LD; Marin O; Vanoni M; Pinna LA; Alberghina L
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1040-8. PubMed ID: 16168390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognized sequence and conformation in design of linear peptides as a competitive inhibitor for HMG-CoA reductase.
    Pak VV; Koo M; Yun L; Kwon DY
    J Mol Recognit; 2007; 20(3):197-203. PubMed ID: 17486664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome.
    Kaiser M; Groll M; Siciliano C; Assfalg-Machleidt I; Weyher E; Kohno J; Milbradt AG; Renner C; Huber R; Moroder L
    Chembiochem; 2004 Sep; 5(9):1256-66. PubMed ID: 15368577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
    Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
    Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic optimization of signal transduction via intrinsic disorder.
    Espinoza-Fonseca LM
    Mol Biosyst; 2012 Jan; 8(1):194-7. PubMed ID: 22080214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
    Duca JS
    Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
    Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
    J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin B and cyclin A confer different substrate recognition properties on CDK2.
    Brown NR; Lowe ED; Petri E; Skamnaki V; Antrobus R; Johnson LN
    Cell Cycle; 2007 Jun; 6(11):1350-9. PubMed ID: 17495531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
    J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
    Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
    J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.